Heart and Vessels

, Volume 34, Issue 3, pp 527–537 | Cite as

Long-term clinical course after catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy

  • Satoshi Higuchi
  • Koichiro EjimaEmail author
  • Yuichiro Minami
  • Kenjiro Ooyabu
  • Yuji Iwanami
  • Daigo Yagishita
  • Morio Shoda
  • Nobuhisa Hagiwara
Original Article


Atrial fibrillation (AF) in hypertrophic cardiomyopathy (HCM) patients is highly associated with deterioration of their clinical condition, such as worsening heart failure symptoms, and an increased thromboembolic stroke risk and cardiac mortality rate. This study aimed to investigate the long-term clinical course after catheter ablation (CA) in HCM patients with AF. Among 566 primary HCM patients at our institution, 94 who underwent rhythm control therapy to manage AF from 2002 to 2016 were retrospectively analyzed. The eligible patients were divided into two groups: those who managed AF with CA (n = 34) and those without CA (n = 60). The endpoints were the incidence of initial clinical events, including HCM-related death or an unplanned heart failure hospitalization, or new-onset thromboembolic strokes. During a mean follow-up of 5.8 years, 6% in the CA group and 28% in the non-CA group had a progression of the AF type into permanent AF (Log-rank: p = 0.012). In the Kaplan-Meyer curve analyses, the incidence of clinical events was significantly lower in the CA group than non-CA group (p = 0.025). The annual rates for the incidence of clinical events were 1.2% in the CA group and 6.7% in the non-CA group. In a Cox multivariate analysis, CA therapy (adjusted hazard ratio 0.22; 95% confidence interval: 0.05–0.97; p = 0.046) was the only independent predictor of the incidence of clinical events. In conclusion, CA may be associated with a favorable long-term clinical course in HCM patients with AF.


Hypertrophic cardiomyopathy Atrial fibrillation Catheter ablation Heart failure Stroke 



We would like to thank Mr. John Martin for his linguistic assistance in the preparation of this manuscript.

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest to disclose.


  1. 1.
    Masri A, Kanj M, Thamilarasan M, Wazni O, Smedira NG, Lever HM, Desai MY (2017) Outcomes in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a survival meta-analysis. Cardiovasc Diagn Ther 7:36–44CrossRefGoogle Scholar
  2. 2.
    Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ (2001) Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104:2517–2524CrossRefGoogle Scholar
  3. 3.
    Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, Rastegar H, Estes NAM 3rd, Maron MS, Maron BJ (2017) Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation 136:2420–2436CrossRefGoogle Scholar
  4. 4.
    Losi MA, Betocchi S, Grimaldi M, Spampinato N, Chiariello M (1994) Heterogeneity of left ventricular filling dynamics in hypertrophic cardiomyopathy. Am J Cardiol 73:987–990CrossRefGoogle Scholar
  5. 5.
    Siontis KC, Geske JB, Ong K, Nishimura RA, Ommen SR, Gersh BJ (2014) Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Assoc 3:e001002CrossRefGoogle Scholar
  6. 6.
    Yashiro B, Minami Y, Terajima Y, Hagiwara N (2014) Prognostic difference between paroxysmal and non-paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. J Cardiol 63:432–437CrossRefGoogle Scholar
  7. 7.
    Maron MS, Rowin EJ, Olivotto I, Casey SA, Arretini A, Tomberli B, Garberich RF, Link MS, Chan RH, Lesser JR, Maron BJ (2016) Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 67:1399–1409CrossRefGoogle Scholar
  8. 8.
    Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS (2014) Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 64:83–99CrossRefGoogle Scholar
  9. 9.
    Rowin EJ, Maron BJ, Kiernan MS, Casey SA, Feldman DS, Hryniewicz KM, Chan RH, Harris KM, Udelson JE, DeNofrio D, Roberts WC, Maron MS (2014) Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: underrecognized subset of candidates for heart transplant. Circ Heart Fail 7:967–975CrossRefGoogle Scholar
  10. 10.
    Pasqualucci D, Fornaro A, Castelli G, Rossi A, Arretini A, Chiriatti C, Targetti M, Girolami F, Corda M, Orrù P, Matta G, Stefàno P, Cecchi F, Porcu M, Olivotto I (2015) clinical spectrum, therapeutic options, and outcome of advanced heart failure in hypertrophic cardiomyopathy. Circ Heart Fail 8:1014–1021CrossRefGoogle Scholar
  11. 11.
    Haruki S, Minami Y, Hagiwara N (2016) Stroke and embolic events in hypertrophic cardiomyopathy: risk stratification in patients without atrial fibrillation. Stroke 47:936–942CrossRefGoogle Scholar
  12. 12.
    Guttmann OP, Pavlou M, O'Mahony C, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, Garcia-Pavia P, McKenna WJ, Omar RZ, Elliott PM (2015) Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM risk-CVA). Eur J Heart Fail 17:837–845CrossRefGoogle Scholar
  13. 13.
    Guttmann OP, Rahman MS, O'Mahony C, Anastasakis A, Elliott PM (2014) Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart 100:465–472CrossRefGoogle Scholar
  14. 14.
    Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP, Casey SA, Gohman TE, Bongioanni S, Spirito P (2002) Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 39:301–307CrossRefGoogle Scholar
  15. 15.
    Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2379CrossRefGoogle Scholar
  16. 16.
    Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (2011) American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 124:e783–831Google Scholar
  17. 17.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893–2962CrossRefGoogle Scholar
  18. 18.
    Zhao DS, Shen Y, Zhang Q, Lin G, Lu YH, Chen BT, Shi LS, Huang JF, Lu HH (2016) Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. Europace 18:508–520CrossRefGoogle Scholar
  19. 19.
    Providencia R, Elliott P, Patel K, McCready J, Babu G, Srinivasan N, Bronis K, Papageorgiou N, Chow A, Rowland E, Lowe M, Segal OR, Lambiase PD (2016) Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart 102:1533–1543CrossRefGoogle Scholar
  20. 20.
    Bassiouny M, Lindsay BD, Lever H, Saliba W, Klein A, Banna M, Abraham J, Shao M, Rickard J, Kanj M, Tchou P, Dresing T, Baranowski B, Bhargava M, Callahan T, Tarakji K, Cantillon D, Hussein A, Marc Gillinov A, Smedira NG, Wazni O (2015) Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy. Heart Rhythm 12:1438–1447CrossRefGoogle Scholar
  21. 21.
    Santangeli P, Di Biase L, Themistoclakis S, Raviele A, Schweikert RA, Lakkireddy D, Mohanty P, Bai R, Mohanty S, Pump A, Beheiry S, Hongo R, Sanchez JE, Gallinghouse GJ, Horton R, Dello Russo A, Casella M, Fassini G, Elayi CS, Burkhardt JD, Tondo C, Natale A (2013) Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: long-term outcomes and mechanisms of arrhythmia recurrence. Circ Arrhythm Electrophysiol 6:1089–1094CrossRefGoogle Scholar
  22. 22.
    Eriksson MJ, Sonnenberg B, Woo A, Rakowski P, Parker TG, Wigle ED, Rakowski H (2002) Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 39:638–645CrossRefGoogle Scholar
  23. 23.
    Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Nielsen JC, Curtis AB, Davies DW, Day JD, d'Avila A, de Groot NMSN, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T (2017) 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 14:e275–e444CrossRefGoogle Scholar
  24. 24.
    Ejima K, Henmi R, Iwanami Y, Yagishita D, Shoda M, Hagiwara N (2017) Comparison of the efficacy of empiric thoracic vein isolation for the treatment of paroxysmal and persistent atrial fibrillation in patients without structural heart disease. J Cardiovasc Electrophysiol 28:266–272CrossRefGoogle Scholar
  25. 25.
    Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ (2000) Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 84:476–482CrossRefGoogle Scholar
  26. 26.
    Petersen SE, Jerosch-Herold M, Hudsmith LE, Robson MD, Francis JM, Doll HA, Selvanayagam JB, Neubauer S, Watkins H (2007) Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation 115:2418–2425CrossRefGoogle Scholar
  27. 27.
    Stafford WJ, Trohman RG, Bilsker M, Zaman L, Castellanos A, Myerburg RJ (1986) Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol 7:701–704CrossRefGoogle Scholar
  28. 28.
    Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A (2000) Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 31:988–998CrossRefGoogle Scholar
  29. 29.
    Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, Kellen JC, Klein RC, Krahn AD, Mickel M, Mitchell LB, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG, Investigators AFFIRM (2004) Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109:1509–1513CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of CardiologyTokyo Women’s Medical UniversityTokyoJapan

Personalised recommendations